Based on the fact that abrogation of TNFα does not affect the potent IL-12 antitumor capacity, this work supports the development of alternatives approaches and therapies capable of reducing toxicity, including the addition of approved TNFα antagonists (infliximab, adalimumab, etc), when using IL-12 in cancer patients. This evidence concerns the gene TNF and cancer.